Abstract
Hormone responsiveness is a critical determinantof breast cancer progression and management, and theresponse to endocrine therapy is highly correlated withthe estrogen receptor (ER)3 and progesterone receptor (PR) status of tumor cells. Thus, keyareas of study in breast cancer are those mechanismsthat regulate ER and PR expression in normal andmalignant breast tissues. One-third of all breastcancers lack ER and PR; these conditions are associatedwith less differentiated tumors and poorer clinicaloutcome. In addition, approximately one-half ofER-positive tumors lack PR protein and patients withthis phenotype are less likely to respond tohormonal therapies than those whose tumors express bothreceptors. Since PR is induced by ER; its presence is amarker of a functional ER. In this review, we will discuss possible mechanisms for loss of ER andPR gene expression, especially structural changes withineach gene including deletions, polymorphisms ormethylation. Improved understanding of the pathways that lead to loss of ER and/or PR proteinsshould allow the development of better predictiveindicators as well as novel therapeutic approaches totarget these hormone-independent cancers.
Similar content being viewed by others
References
F. Borellini and T. Oka (1989). Growth control and differentiation in mammary epithelial cells. Environ. Health Perspect 80:85 99.
D. L. Ricketts, G. Turnbull, R. Ryall, N. S. B. Bakshi, N. S. B. Raswon, J-C. Gazet, C. Nolan, and R. C. Coombes (1991). Estrogen and progesterone receptor in the normal female breast. Cancer Res. 51:1817-1822.
O. W. Peterson, P. E. Hoyer, and B. Van Deurs (1987). Frequency and distribution of estrogen positive cells in normal, non-lactating human breast tissue. Cancer Res. 47:5748-5751.
C. Markopoulus, U. Berger, P. Wilson, J. Gazet, and R. C. Coombes (1988). Oestrogen receptor content of normal breast cells and breast carcinoma throughout the menstrual cycle. Brit. Med. J. 296:1349-1351.
C. W. Daniels, G. B. Silberstein, and P. Strickland (1987). Direct action of 17-beta estradiol on mouse mammary ducts analyzed by sustain release implants and steroid autoradiography. Cancer Res. 47:6052-6057.
G. B. Silberstein, K. Van Horn, G. Shyamala, and C.W. Daniels (1994). Essential role of endogenous estrogen in directly stimulating mammary growth demonstrated by implants containing pure anti-estrogens. Endocrinology 134:84-90.
K. S. Korach (1994). Insights from the study of animals lacking functional estrogen receptor. Science 266:1524-1527.
J. P. Lydon, F. J. DeMayo, C. R. Funk, S. K. Mani, A. R. Hughes, C. A. Montgomery, Jr., G. Shyamala, O. M. Conneely, and B.W. O' Malley (1995). Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev. 9:2266-2278.
J. P. Lydon, F. J. DeMayo, O. M. Conneely, and B.W. O' Malley (1996). Reproductive phenotypes of the progesterone receptor null mutant mouse. J. Steroid Biochem. Mol. Biol. 56:67-77.
H. Gronemeyer (1991). Transcription activation by estrogen and progesterone receptors. Ann. Rev. Genet. 25:89-123.
L. Tora, J. White, C. Brou, D. Tasset, N. Webster, E. Scheer, and P. Chambon (1989). The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59:477-487.
S. Adler, M. L. Waterman, and M. G. Rosenfeld (1988). Steroid receptor-mediated inhibition of rat prolactin gene expression does not require the receptor DNA-binding domain. Cell 52:685-695.
M. Montano, V. Muller, A. Trobaugh, and B. S. Katzenellenbogen (1995). The carboxy-termina l F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol. Endocrinol. 9:814-825.
B. A. Lieberman (1997). The estrogen receptor activity: dependence on multiple protein-protein interactions. Crit. Rev. Euk. Gene Exp. 7:43-59.
W. L. Kraus, E. M. McInerney, and B. S. Katzenellenbogen (1995). Ligand-dependent, transcriptionally productive association of the amino-and carboxyl-termi nal regions of a steroid hormone nuclear receptor. Proc. Natl. Acad. Sci. USA 92:12314-12318.
L. D. Read, C. E. Snider, J. S. Miller, G. L. Greene, and B. S. Katzenellenbogen (1988). Ligand-modulat ed regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines. Mol. Endocrinol. 2:263-271.
S. B. Jakowlew, R. Breathnach, J. M. Teltsa, P. Masaikowski, and P. Chambon (1984). Sequence of pS2 mRNA induced by estrogen in the human breast cancer cell line, MCF-7. Nucleic Acids Res. 12:2861-2878.
D. Dubik and R. P. C. Shiu (1988). Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. J. Biol. Chem. 263:12705-12708.
S. E. Bates, N. E. Davidson, E. M. Valverius, C. E. Freter, R. B. Dickson, J. P. Tam, J. E. Kudlow, M. E. Lippman, and D. S. Salomon (1988). Expression of transforming growth factor and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol. Endocrinol. 2:543-555.
A. Bailly, C. Le Page, M. Rauch, and E. Milgrom (1986). Sequence specific DNA binding of progesterone receptor to the uteroglobin gene. EMBO J. 5:3235-3241.
V. Lamian, B. Y. Gonzalez, F. J. Michel, and R. C. M. Simmen (1993). Non-consensus progesterone response elements medi-ate the progesterone-reg ulated endometrial expression of the uteroferrin gene. J. Steroid Biochem. Mol. Biol. 46:439-450.
J. G. Gao, J. Mazella, D. R. Powell, and L. Tseng (1994). Identification of a distal regulatory sequence of the human IGFBP-1 gene promoter and regulation by progesterone recep-tor in a human endometrial adenocarcinoma cell line. DNA Cell Biol. 13:829-837.
W. L. McGuire (1978). Hormone receptors: their role in pre-dicting prognosis and response to endocrine therapy. Seminar Oncol. 5:428-433.
G. L. Greene, P. Hilna, M. Waterfield, A. Baker, Y. Hort, and J. Shine (1986). Sequence and expression of human estrogen receptor complementary DNA. Science 231:1150-1154.
S. Green, P. Walter, V. Kumar, A. Krust, P-M. Bornet, P. Argos, and P. Chambon (1986). Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320:134-139.
M. Ponglikitmonkol, S. Green, and P. Chambon (1988). Genomas. mic organization of the human oestrogen receptor gene. EMBO J. 7:3385-3388.
H. Fujii, C. Marsh, P. Cairns, D. Sidransky, and E. Gabrielson (1996). Genetic divergence in the clonal evolution of breast cancer. Cancer Res. 56:1493-1497.
H. Iwase, J. M. Greenman, D. M. Barnes, L. Bobrow, S. Hodg-son, and C. G. Mathew (1995). Loss of heterozygosity of the oestrogen receptor gene in breast cancer. Brit. J. Cancer 71:448-450.
C. K. Watts, M. L. Handel, R. J. B. King, and R. L. Sutherland (1992). Oestrogen receptor gene structure and function in breast cancer. J. Steroid Biochem. Mol. Biol. 41:3-9.
S. M. Hill, S. A. W. Fuqua, G. C. Chamness, G. L. Greene, and W. L. McGuire (1989). Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism. Cancer Res. 49:145-148.
F. F. Parl, D. R. Cavener, and W. D. Dupont (1989). Genomic DNA analysis of the estrogen receptor gene in breast cancer. Breast Cancer Res. Treat. 14:57-64.
L. Yaich, W. D. Dupont, D. R. Cavener, and F. F. Parl (1992). Analysis of the PvuII restriction fragment polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. Cancer Res. 52:77-83.
N. Roodi, L. R. Bailey, W-Y. Kao, C. S. Verrier, C. J. Yee, W. D. Dupont, and F. F. Parl (1995). Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J. Natl. Cancer Inst. 87:446-451.
T. M. Garcia, T. M. Sanchez, J. L. Cox, P. A. Shaw, J. B. Ross, S. Lehre, and B. Schachter (1989). Identification of a variant form of the human estrogen receptor with an amino acid replacement. Nucleic Acid Res. 17:8364.
Q.-X. Zhang, A. Borg, D. M. Wolf, S. Oesterreich, and S. A. W. Fuqua (1997). An estrogen receptor mutant wiath strong hormone-independ ent activity from a metastatic breast cancer. Cancer Res. 57:1244-1249.
P. S. Karnik, S. Kulkarni, X-P. Liu, G. T. Budd, and R. M. Bukowski (1994). Estrogen receptor mutation in tamoxifen-resistant cancer. Cancer Res. 54:349-353.
D. M. Wolf and V. C. Jordan (1994) The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res. Treat. 31:129-138.
W. L. McGuire, G. C. Chamness, and S. A. W. Fuqua (1992). Estrogen receptor variants in clinical breast cancer. Mol. Endocrinol. 5:1571-1577.
M. L. Graham, N. L. Kreet, L. A. Miller, K. K. Leslie, D. F. Gordon, W. M. Wood, L. L. Wei, and K. B. Horwitz (1990). T47Dco cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancer hormone resistance. Cancer Res. 50:6208-6217.
J. J. Pink, S. Y. Jiang, M. Fritsch, and V. C. Jordan (1995). A unique MCF-7 human breast cancer cell line expressing an 80 kD estrogen receptor. Proc. Am. Assoc. Cancer Res. 35:276.
Y. L. Ottaviano, J-P. Issa, F. F. Parl, H. S. Smith, S. B. Baylin, and N. E. Davidson (1994). Methylation of the estrogen recep-tor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 54:2552-2555.
R. J. Weigel and E. C. deConinck (1993). Transcriptional con-trol of estrogen receptor in estrogen receptor negative breast carcinoma. Cancer Res. 53:3472-3474.
C. Carmeci, E. C. deConinck, T. Lawton, D. A. Bloch, and R. J. Weigel (1997). Analysis of estrogen receptor messenger RNA in breast carcinomas from archival specimens is predictive of tumor biology. Am. J. Pathol. 150:1563-1570.
E. C. deConinck, L. A. McPherson, and R. J. Weigel (1995). Transcriptional control of estrogen receptor in breast carcinomas. Mol. Cell. Biol. 15:2191-2196.
L. A. McPherson, V. R. Baichwal, and R. J. Weigel (1997). Identification of ERF-1 as a member of the AP2 transcription factor family. Proc. Natl. Acad. Sci. USA 94:4342-4347.
A. P. Bird (1986). CpG-rich islands and the function of DNA methylation. Nature 321:209-213.
E. Li, C. Beard, and R. Jaenisch (1993). Role of DNA methyla-tion in genomic imprinting. Nature 366:362-365.
T. Mohandas, R. S. Sparkes, and L. J. Shapiro (1981). Reactiva-tion of an inactive human X chromosome: evidence for X inactivation by DNA methylation. Science 211:393-396.
H. Cedar (1988). DNA methylation and gene activity. Cell 53:3.
P. W. Laird and R. Jainisch (1996). The role of DNA methyla-tion in cancer genetics and epigenetics. Ann. Rev. Genet. 30:441-464.
J. G. Herman, F. Latif, Y. Weng, M. I. Lerman, B. Zbar, S. Liu, D. Samid, D. S. Duan, J. R. Gnarra, W. M. Linehan, and S. B. Baylin (1994). Silencing of the VHL-tumor suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA 91:9700-9704.
J. G. Herman, A. Merlo, L. Mao, R. G. Lapidus, J-P. Issa, N. E. Davidson, D. Sidransky, and S. B. Baylin (1995). Inactivation of the CDKN2/p16/M ST1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55:4525-4530.
J. G. Herman, J. Jen, A. Merlo, and S. B. Baylin (1996). Hypermethylati on-associated inactivation indicates a tumor suppressor role for p15INK4B1. Cancer Res. 56:722-727.
W. H. Lee, R. A. Morton, J. I. Epstein, J. D. Brooks, P. A. Campbell, G. S. Bova, W. S. Hsieh, W. B. Isaacs, and W. G. Nelson (1994). Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. USA 91:11733-11737.
J. G. Graff, J. G. Herman, R. G. Lapidus, H. E. Chopra, R. Xu, D. F. Jarrard, W. B. Isaacs, P. M. Pitha, N. E. Davidson, and S. B. Baylin (1995). E-cadherin expression is silenced by DNA hypermethylatio n in human breast and prostate carcinoma. Cancer Res. 55:5195-5199.
R. Piva, A. P. Rimondi, S. Hanau, I. Maestri, A. Alvisi, V. L. Kumar, and L. del Senno (1990). Different methylation of oestrogen receptor DNA in human breast carcinomas with and without oestrogen receptor. Brit. J. Cancer 61:270-275.
N. S. Falette, S. A. W. Fuqua, G. C. Chamness, M. S. Cheah, G. L. Greene, and W. L. McGuire (1990). Estrogen receptor gene methylation in human breast tumors. Cancer Res. 50:3974-3978.
A. T. Ferguson, R. G. Lapidus, S. B. Baylin, and N. E. Davidson (1995). Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res. 55:2279-2283.
R. G. Lapidus, A. T. Ferguson, Y. L. Ottaviano, F. F. Parl, H. S. Smith, S. A. Weitzman, S. B. Baylin, J-P. J. Issa, and N. E. Davidson (1996). Methylation of estrogen and progesterone receptor genes 5′ CpG islands correlates with lack of ER and PR gene expression in breast tumors. Clinical Cancer Res. 2:805-810.
M. F. Rousseau-Merck, M. Misrahi, E. Loosfelt, E. Milgrom, and R. von Beger (1987). Localization of the human progester-one receptor gene to chromosome 11q22q23. Human Genet. 77:280-282.
I. P. Tomlinson, H. Nicolai, E. Solomon, and W. F. Bodmer (1996). The frequency and mechanism of loss of heterozygosity on chromosome 11q in breast cancer. J. Pathol. 180:38-43.
R. Winqvist, G. M. Hampton, A. Mannermaa, G. Blanco, M. Alavaikko, H. Kiviniemi, P. J. Taskinen, G. A. Evans, F. A. Wright, I. Newsham, and W. K. Cavenee (1995). Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastases. Cancer Res. 55:2660-2664.
S. A. W. Fuqua, S. M. Hill, G. Chamness, M. G. Benedix, G. L. Greene, B. W. O' Malley, and W. L. McGuire (1991). Progesterone receptor gene restriction fragment length poly-morphism in human breast tumors. J. Natl. Cancer Inst. 83:1157-1160.
T. P. Manolitsas, P. Englefield, D.M. Eccles, and I. G. Campbell (1997). No association of a 306-bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer. Brit. J. Cancer 75:1398-1399.
K. L. Satya-Prakash, S. Pathak, T. C. Hsu, M. Olive, and R. Cailleau (1981). Cytogenetic analysis on eight human breast tumor cell lines: high frequencies of 1q, 11q and HeLa-like marker chromosome. Cancer Genet. Cytogenet. 3:61-73.
C. Mies and W. Voigt (1996). Sequence analysis of the DNA binding domain of the estrogen receptor gene in ER(+)/PR(-) breast cancer. Diagnostic Mol. Pathol. 5:39-44.
L. Kastner, A. Krust, B. Turcotte, U. Stropp, L. Tora, H. Gro-nemeyer, and P. Chambon (1990). Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 9:1603-1614.
M. Misrahi, P. Venecie, P. Saugier-Veber, S. Sars, P. Dessen, and E. Milgrom (1993). Structure of the human progesterone receptor gene. Biochim. Biophys Acta 1216:289-292.
Rights and permissions
About this article
Cite this article
Lapidus, R.G., Nass, S.J. & Davidson, N.E. The Loss of Estrogen and Progesterone Receptor Gene Expression in Human Breast Cancer. J Mammary Gland Biol Neoplasia 3, 85–94 (1998). https://doi.org/10.1023/A:1018778403001
Issue Date:
DOI: https://doi.org/10.1023/A:1018778403001